1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Regenxbio On Track For Pivotal Study After Interim RGX-202 DMD Data

 
• By Alaric DeArment

The company is hoping to become second to market with a DMD gene therapy after Sarepta’s Elevidys, which recently had a label expansion.

• Source: Shutterstock

Regenxbio Inc. is closer to becoming a potential competitor to Sarepta Therapeutics, Inc. in gene therapy for Duchenne muscular dystrophy (DMD) with Phase I/II interim data for its candidate RGX-202. Despite Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) currently having a monopoly on gene therapy treatment for DMD, there is likely enough room for RGX-202 to be second to market.

The Rockville, MD-based biotech announced interim data from the Phase I/II AFFINITY DUCHENNE trial in DMD patients aged 1-11. RGX-202...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

More from Advanced Therapies